The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Preclinical CRO Market Increase Between 2026 And 2030?
The preclinical CRO market size has experienced robust growth in recent years. It is projected to expand from $6.25 billion in 2025 to $6.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. This historical increase can be attributed to several factors, including escalating pharmaceutical R&D investments, the growing complexity of drug development pipelines, a heightened reliance on animal testing for safety validation, the expansion of biotechnology research activities, and more stringent regulatory scrutiny on preclinical data.
The preclinical cro market is projected to experience substantial expansion in the coming years. It is anticipated to reach $9.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This anticipated growth during the forecast period can be attributed to several factors, including the escalating demand for precision medicine research, a heightened emphasis on developing drugs for rare diseases, the broadening of biologics and cell therapy pipelines, the increasing integration of digital preclinical platforms, and a rise in collaborations between pharmaceutical firms and CROs. Key trends characterizing this period involve the growing uptake of integrated preclinical study services, a heightened need for specialized expertise in advanced animal models, the increasing trend of outsourcing early-stage drug development, the expansion of toxicology capabilities aligned with regulatory standards, and a greater emphasis on designing studies based on data.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10303&type=smp
Which Strategic Drivers Are Supporting The Preclinical CRO Market Development?
The rising requirement for preclinical studies is projected to boost the expansion of the preclinical CRO market in the future. Preclinical trials encompass investigations into medicines or treatments for conditions before they are tested on human participants. These studies frequently focus on new medical devices, prescribed drugs, and diagnostic tools, with key goals being to determine an initial safe dosage for human trials and assess the product’s potential for toxicity. Such trials are crucial in drug development, and their significance is growing due to the heightened focus on the safety and effectiveness of new pharmaceuticals. For example, in February 2024, IQVIA, a US-based company that provides services to the health information technology and clinical research sectors, reported an increase in clinical development productivity in 2023. Globally, a total of 69 novel active substances (NASs) were introduced in 2023, which was 6 more than the prior year, and this included 24 first-in-class launches in the U.S. Consequently, the escalating need for preclinical trials is propelling the expansion of the preclinical CRO market into the future.
What Segment Types Are Included In The Preclinical CRO Market Analysis?
The preclinical cro market covered in this report is segmented –
1) By Service: Bioanalysis And DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others Services
2) By Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By Animal Model: Small Animal Model, Large Animal Model
4) By Model System: In Vivo, In Vitro
5) By End User: Biopharmaceutical Companies, Government And Academic Institutes, Medical Device Companies, Other End-users
Subsegments:
1) By Bioanalysis And DMPK Studies: Pharmacokinetics Studies, Pharmacodynamics Studies, Drug Metabolism Studies
2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Reproductive Toxicity Testing
3) By Compound Management: Sample Management, Inventory Management, Formulation Services
4) By Chemistry: Medicinal Chemistry, Analytical Chemistry, Synthetic Chemistry
5) By Safety Pharmacology: Cardiovascular Safety Studies, Central Nervous System Safety Studies, Respiratory Safety Studies
6) By Other Services: Regulatory Consulting, Project Management, Data Management Services
Which Trends Are Influencing The Direction Of The Preclinical CRO Market?
Key companies engaged in the preclinical assets market are concentrating on establishing strategic alliances to accelerate the identification and development of innovative drug candidates. These partnerships enable the sharing of research expertise, access to novel targets, and the progression of early-stage preclinical assets. For example, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, an India-based research and drug development company, announced an expanded strategic collaboration to continue advancing several innovative preclinical and early-stage clinical assets. This partnership builds upon the existing collaboration between AbbVie and Scripps Research. Furthermore, Calibr will present AbbVie with a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.
Which Companies Are Engaged In The Preclinical CRO Market Environment?
Major companies operating in the preclinical cro market are Eurofins Scientific SE, WuXi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Laboratory Corporation Of America Holdings, Intertek Group plc, Crown Bioscience International, Cynbiose, AmplifyBio LLC, Vivotecnia SL, Altasciences Company Inc, Pharmaceutical Product Development LLC, Parexel International Corporation, Envigo RMS Holding Corporation, Veeda Clinical Research Ltd, ICON plc, Kunming Biomed International Ltd, PharmaLegacy Laboratories, NorthEast BioAnalytical Laboratories LLC, MDS Pharma Services, MPI Research, Toxikon Corporation, BioReliance Corporation, Covance Inc, Syngene International Limited
Access The Complete Preclinical CRO Market Report:
https://www.thebusinessresearchcompany.com/report/preclinical-cro-global-market-report
Which Region Is The Primary Market For The Preclinical CRO Market?
North America was the largest region in the preclinical CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global preclinical CRO market during the forecast period. The regions covered in the preclinical cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Preclinical CRO Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=10303&type=smp
Browse Through More Reports Similar to the Global Preclinical CRO Market 2026, By The Business Research Company
Asset Management Market 2026
https://www.thebusinessresearchcompany.com/report/asset-management-market
Digital Asset Custody Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-asset-custody-global-market-report
Enterprise Asset Management Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/enterprise-asset-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









